Press Releases
Sep 22, 2023

– Trial results to be submitted for presentation at upcoming medical meeting – TOKYO and BOTHELL, Wash., Sept. 22, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki...

Sep 20, 2023

GA is a form of age-related macular degeneration (AMD) that causes irreversible vision loss, affecting approximately 1.5 million people in the United States1,2 Eric and his mother, Jamey, are...

Sep 18, 2023

GATHER2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham IZERVAY 24-month safety data were consistent with 12-month...


Jul 11, 2023

Our consistent top score demonstrates our continuing effort to create an inclusive culture for people with disabilities. For the fourth year in a row, Astellas has been included in the Disability...

May 5, 2023

As a global pharmaceutical company, Astellas takes the fight against cancer personally and is deeply committed to our employees and customers who are a part of the oncology community. Fifty...

Apr 25, 2023

Astellas Executive Vice President and Head of Medical Affairs Shontelle Dodson and Vice President, Head of Biopharma Development Marci English were recently featured in an Axios Smart Brevity...


Stay Connected

Get only the email alerts you want.


Media Contacts


For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.


Astellas on Twitter
Download Fact Sheet
Explore U.S. Products